Literature DB >> 29124557

Baseline predictors of DMT reinitiation among patients with multiple sclerosis following an MI-CBT intervention.

Joanie Thelen1, Amanda Bruce2,3, Delwyn Catley3, Sharon Lynch4, Kathy Goggin5,6, Andrea Bradley-Ewing5, Morgan Glusman7, Abigail Norouzinia7, Lauren Strober8, Jared Bruce7.   

Abstract

Patients with multiple sclerosis (MS) are often nonadherent to their disease modifying therapy (DMT). While recent studies demonstrate enhanced DMT adherence following intervention grounded in motivational interviewing (MI), little is known about how to address DMT reinitiation among MS patients who have prematurely discontinued DMT against medical advice and do not intend to reinitiate. We examined baseline predictors of DMT reinitiation among patients with MS who discontinued medications against medical advice following a telephone-based MI and Cognitive Behavioral Therapy (MI-CBT) intervention. Following MI-CBT intervention, 66 patients reported whether or not they opted to reinitiate DMT. Rate of disease progression (β = 0.295) and perceived personal control (β = - 0.131) emerged as unique significant predictors of DMT reinitiation following intervention. Clinical characteristics and health-related beliefs may be used to prospectively identify patients most likely to reinitiate DMT following MI-CBT intervention, furthering the goal of preserving brain health and preventing neurologic decline in MS via appropriate DMT utilization. Further study is warranted to delineate potential mediators and moderators of DMT reinitiation outcomes.

Entities:  

Keywords:  Adherence; Cognitive behavioral therapy; DMT; Health beliefs; Motivational interviewing; Multiple sclerosis

Mesh:

Substances:

Year:  2017        PMID: 29124557     DOI: 10.1007/s10865-017-9900-9

Source DB:  PubMed          Journal:  J Behav Med        ISSN: 0160-7715


  30 in total

1.  Treatment satisfaction in multiple sclerosis.

Authors:  Bonnie I Glanz; Alexander Musallam; David J Rintell; Tanuja Chitnis; Howard L Weiner; Brian C Healy
Journal:  Int J MS Care       Date:  2014

2.  Psychiatric co-morbidity in multiple sclerosis: The risk of depression and anxiety before and after MS diagnosis.

Authors:  Huong Hoang; Bjarne Laursen; Elsebeth N Stenager; Egon Stenager
Journal:  Mult Scler       Date:  2015-06-03       Impact factor: 6.312

3.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

4.  Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report.

Authors:  Jared M Bruce; Laura M Hancock; Sharon G Lynch
Journal:  Mult Scler       Date:  2009-12-07       Impact factor: 6.312

5.  Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

Authors:  R H S R Roxburgh; S R Seaman; T Masterman; A E Hensiek; S J Sawcer; S Vukusic; I Achiti; C Confavreux; M Coustans; E le Page; G Edan; G V McDonnell; S Hawkins; M Trojano; M Liguori; E Cocco; M G Marrosu; F Tesser; M A Leone; A Weber; F Zipp; B Miterski; J T Epplen; A Oturai; P Soelberg Sørensen; E G Celius; N Téllez Lara; X Montalban; P Villoslada; A M Silva; M Marta; I Leite; B Dubois; J Rubio; H Butzkueven; T Kilpatrick; M P Mycko; K W Selmaj; M E Rio; M Sá; G Salemi; G Savettieri; J Hillert; D A S Compston
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

6.  Appraisals of control and predictability in adapting to a chronic disease.

Authors:  G Affleck; H Tennen; C Pfeiffer; J Fifield
Journal:  J Pers Soc Psychol       Date:  1987-08

7.  Factors that influence adherence with disease-modifying therapy in MS.

Authors:  Katherine Treadaway; Gary Cutter; Amber Salter; Sharon Lynch; James Simsarian; John Corboy; Douglas Jeffery; Bruce Cohen; Ken Mankowski; Joseph Guarnaccia; Lawrence Schaeffer; Roy Kanter; David Brandes; Charles Kaufman; David Duncan; Ellen Marder; Arthur Allen; John Harney; Joanna Cooper; Douglas Woo; Olaf Stüve; Michael Racke; Elliot M Frohman
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

8.  Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.

Authors:  J D Fisk; P G Ritvo; L Ross; D A Haase; T J Marrie; W F Schlech
Journal:  Clin Infect Dis       Date:  1994-01       Impact factor: 9.079

9.  Disease-modifying therapy in multiple sclerosis: update and clinical implications.

Authors:  Douglas S Goodin
Journal:  Neurology       Date:  2008-12-09       Impact factor: 9.910

10.  Multiple sclerosis: overview of disease-modifying agents.

Authors:  Alessandro Finkelsztejn
Journal:  Perspect Medicin Chem       Date:  2014-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.